Drugs / Combination: Fruquintinib + FOLFIRI
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05522738 Background | Aug 2022 → Dec 2024 | colorectal cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Combination: Fruquintinib + FOLFIRI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05522738 ↗ |
| Route | Intravenous | “LV：200 mg/m2, i.v., d1, q2w” NCT05522738 ↗ |